RxDoctor Payments Data

Benjamin Choi, MD

Urology · New York, NYNPI 1528101607

Payments from drug & device makers

$8,765in general payments, 2019–2025

Across 27 payments — averaging $324.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$8K
  • Astellas Pharma US Inc$310
  • Johnson & Johnson$261
  • Abbott$125
  • Progenics Pharmaceuticals, Inc.$121
  • Koelis Inc.$121
  • plus $207 from 5 others

What the payments were for

  • Food & beverage$90110%
  • Education$2433%
  • Gifts$7,62187%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Olympus America Inc.1$7,621
Astellas Pharma US Inc7$310
Johnson & Johnson(2 entities)2$261
Abbott1$125
Progenics Pharmaceuticals, Inc.1$121
Koelis Inc.1$121
Endo Pharmaceuticals Inc.9$116
Ferring Pharmaceuticals Inc.1$30
AbbVie2$24
Hollister Incorporated1$21
Endo USA, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,765 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$9,246
Medicare patients
19
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron185$95,186
GemtesaVibegron55$26,854
Silodosin238$18,973
Tamsulosin Hcl480$10,183
Finasteride639$10,014
Potassium Citrate ErPotassium Citrate31$5,683
RapafloSilodosin14$5,642
Cefpodoxime Proxetil102$3,042
Tadalafil79$2,734
Methenamine Hippurate38$2,510
Testosterone11$2,449
Dutasteride53$1,820
Estradiol11$863
Tolterodine Tartrate ErTolterodine Tartrate24$831
Solifenacin Succinate20$642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$310$95,186185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →